|
|
|
|
Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Re
Christina M.Schilder, Caroline Seynaeve, Louk V. Beex, Willem Boogerd, Sabine C. Linn, Chad M. Gundy, Hilde M. Huizenga, Johan W. Nortier, Cornelis J. van de Velde, Frits S. van Dam, and Sanne B. Schagen* From the Departments of Psychosocial...
|
|
|
Pfizer updates trial results for Aromasin in switch & upfront settings
Pfizer announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free...
|
|
|
US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium
THE WOODLANDS, Texas, Dec.14 /PRNewswire/ -- Seven leading cancer physicians and investigators affiliated with US Oncology Research participated in studies that were presented orally at the 2009 San Antonio Breast Cancer Symposium, held Dec. 9-13 at the...
|
|
|
Pfizer Announces Updated Trial Results for Aromasin (exemestane tablets) In Switch And Upfront Settings
Additional Results from the 91-Month Median Follow-up of the Intergroup Exemestane Study (IES) and the Tamoxifen, Exemestane, Adjuvant, Multicenter (TEAM) Study Demonstrate Benefits of Aromasin in Estrogen-Receptor Positive/Unknown Postmenopausal...
|
|
|
Pfizer Announces Updated Trial Results for AROMASIN (exemestane tablets) In Switch And Upfront Settings
2009-12-1011:42ET - News Release Additional Results from the 91-Month Median Follow-up of the Intergroup Exemestane Study (IES) and the Tamoxifen, Exemestane, Adjuvant, Multicenter (TEAM) Study Demonstrate Benefits of Aromasin in Estrogen-Receptor...
|
|
|
Pfizer Oncology to present data of expanded breast cancer porfolio at San Antonio Breast Cancer Symposium
Pfizer Oncology announced that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient...
|
|
|
Pfizer To Present Clinical Data From Expanded Breast Cancer Portfolio At The San Antonio Breast Cancer Symposi
Results from Studies in Early Breast Cancer and Advanced Disease to be Presented NEW YORK--(BUSINESS WIRE)--Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast...
|
